Celyad Oncology SA · EURONEXT:CYAD
Celyad Oncology SA — European Hematology Association Virtual Congress 2021
24 slides from Celyad Oncology SA's conference presentation, Jun 11, 2021
Slide 1: Redefining Allogeneic CAR Ts Using a Non-Gene Edited Approach
European Hematology Association Virtual Congress 2021 Redefining Allogeneic CAR Ts Using a William Blair Growth Stock Conference Non-Gene Edited Approach June 11, 2021
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks and uncertainties which might cause ac
Slide 3: EHA 2021 Virtual Webcast – Agenda
EHA 2021 Virtual Webcast – Agenda Topic Discussant Filippo Petti Welcome & Introductions Chief Executive Officer David Gilham, Ph.D. shRNA and CYAD-211 Overview Chief Scientific Officer Sébastien Anguille, M.D. IMMUNICY-1 Phase 1 Trial – Preliminary Data University of Antwerp Charles Morris, M.D. Fi
Slide 4: shRNA and CYAD-211 Overview
David Gilham, Ph.D. Chief Scientific Officer shRNA and CYAD-211 Overview
Slide 5: shRNA – Non-gene Editing Technology to Engineer Allogeneic CAR Ts
shRNA – Non-gene Editing Technology to Engineer Allogeneic CAR Ts • Short hairpin RNA (shRNA) interferes with the expression of the T Cell Receptor (TCR) through targeting of the CD3ζ subunit 4
Slide 6: CYAD-211 – shRNA-based Allogeneic CAR T Candidate for r/r MM
CYAD-211 – shRNA-based Allogeneic CAR T Candidate for r/r MM Background on CYAD-211 • CYAD-211 is our first allogeneic CAR T candidate using shRNA technology utilizing our All-in-One vector approach • CYAD-211 co-expresses: • CAR – BCMA specific engager • Allogeneic technology – single shRNA targeti
Slide 7: CYAD-211 – Anti-Tumor Activity With No Evidence of GvHD
CYAD-211 – Anti-Tumor Activity With No Evidence of GvHD • Anti-BCMA CAR T cells with shRNA targeting CD3ζ component exhibited no signs of TCR activation with anti-tumor activity in preclinical models • No demonstrable evidence of GvHD when CYAD-211 was infused in sub-lethally irradiated NSG mice, th
Slide 8: shRNA Knocks Down TCR Expression to Undetectable Levels
shRNA Knocks Down TCR Expression to Undetectable Levels Clinical-grade CYAD-211 • CYAD-211 cell bank generated through TCR Expression a single production run using a proportion of a single healthy donor 99.9% TCR- apheresis • Efficient knock down of cell surface TCR expression to undetectable levels
Slide 9: shRNA as a Novel Allogeneic Technology for CAR T
shRNA as a Novel Allogeneic Technology for CAR T Keys to establishing proof-of-concept ❑ No evidence of GvHD ❑ Initial clinical activity ❑ Cell engraftment GvHD: Graft-versus-Host Disease. 8
Slide 10: IMMUNICY-1 Phase 1 Trial – Preliminary Data
Sébastien Anguille, M.D. University of Antwerp IMMUNICY-1 Phase 1 Trial – Preliminary Data
Slide 11: CYAD-211 – IMMUNICY-1 First-in-Human Trial
CYAD-211 – IMMUNICY-1 First-in-Human Trial Open-label, Phase 1 dose-escalation trial in r/r multiple myeloma patients Study Design Treatment Schedule • Primary objective: • Safety and identification of recommended dose of CYAD-211 • Secondary objective: • Clinical anti-tumor activity and CYAD-211 ce
Slide 12: IMMUNICY-1 – Patient Demographics and Clinical Characteristics
IMMUNICY-1 – Patient Demographics and Clinical Characteristics Patient Background • Six patients enrolled across first two dose levels • Three of six patients showed high-risk cytogenetics according to mSMART • Four of six patients were refractory to last line of therapy • Heavily pre-treated patien
Slide 13: CYAD-211 – Preliminary Data Show Favorable Tolerability Profile
CYAD-211 – Preliminary Data Show Favorable Tolerability Profile • No DLTs, no GvHD and no CAR-T-cell-related encephalopathy syndrome (CRES) • One cytokine release syndrome (CRS) Grade 1 (fever) reported at dose level 1 • CRS onset was at the time of the first PR onset in patient #01 • One patient ex
Slide 14: CYAD-211 – Encouraging Initial Clinical Activity in Allogeneic Setting
CYAD-211 – Encouraging Initial Clinical Activity in Allogeneic Setting Duration of Best Response to Treatment • Two patients achieved partial response (PR) • Three additional patients presented with stable disease (SD) Patient bar stopped at the first documented progression of the disease or * when
Slide 15: CYAD-211 – Positive Cell Kinetic Data
CYAD-211 – Positive Cell Kinetic Data CYAD-211 cell levels detected by PCR-based methods in all patients Peripheral Blood Lymphocyte Count CYAD-211 Cell Engraftment • Engraftment was seen in all three patients at dose level 2 at a similar magnitude • Duration and depth of lymphodepletion was variabl
Slide 16: IMMUNICY-1 Preliminary Results – Summary
IMMUNICY-1 Preliminary Results – Summary • Favorable tolerability profile for CYAD-211 was observed at the first two dose-levels (30x106 and 100x106) across six patients enrolled • Two objective responses in conjunction with the current levels of cell engraftment of CYAD-211 are encouraging at these
Slide 17: Final Remarks
Charles Morris, M.D. Chief Medical Officer Final Remarks
Slide 18: Advantages of Non-gene Edited Allogeneic CAR Ts using shRNA
Advantages of Non-gene Edited Allogeneic CAR Ts using shRNA Not all allogeneic CAR Ts are created equal Less potential tolerability issues due to no genome modification All-in-One vector approach (single vector for all elements) Level of gene knockdown Minimized cell can be titrated manipulation Abi
Slide 19: CYAD-211 – Closer Look at Cell Engraftment from IMMUNICY-1
CYAD-211 – Closer Look at Cell Engraftment from IMMUNICY-1 Systemic Cell Engraftment of CYAD-211 • Even with relatively modest doses of lymphodepleting chemotherapy, there is evidence of a dose dependent increase in cell engraftment • Engraftment of shRNA-based allogeneic CAR Ts could offer potentia
Slide 20: shRNA as a Novel Allogeneic Technology for CAR T
shRNA as a Novel Allogeneic Technology for CAR T Keys to establishing proof-of-concept after dose level 1 and 2 ✓ ❑ No evidence of GvHD ✓ ❑ Initial clinical activity ✓ ❑ Cell engraftment GvHD: Graft-versus-Host Disease. 19
Slide 21: Next Steps for CYAD-211 IMMUNICY-1 Trial
Next Steps for CYAD-211 IMMUNICY-1 Trial • Enrollment in dose level 3 (300x106 cells per infusion) ongoing • Additional data from the dose escalation trial are expected during second half 2021 20
Slide 22: CYAD-211 IMMUNICY-1 Trial – Key Takeaways
CYAD-211 IMMUNICY-1 Trial – Key Takeaways • Safety data, clinical activity and cell kinetic data from IMMUNICY-1 support further development of CYAD-211 • Preliminary data support shRNA as a novel allogeneic platform technology to develop future product candidates • Additional next-generation shRNA-
Slide 23: European Hematology Association Virtual Congress 2021
European Hematology Association Virtual Congress 2021 Redefining Allogeneic CAR Ts Using a William Blair Growth Stock Conference Non-Gene Edited Approach June 11, 2021
Slide 24: Celyad Oncology SA contact
European Hematology Redefining Allogeneic Association CAR Ts Using a Virtual Congress Non-Gene Edited2021 Approach Redefining Allogeneic CAR Ts Using a William Blair Growth Stock Conference Non-Gene Edited Approach June 11, 2021 June 11, 2021 Celyad Oncology SA [email protected] +32 10 39 41 00
Celyad Oncology — European Hematology Association Virtual Congress 2021 on 6ix